Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTEGUMENT 3: Roflumilast Cream 0.3% in Moderate to Severe Atopic Dermatitis
NCT07916480Phase 3Not yet recruiting
- Sponsor
- Arcutis Biotherapeutics
- Start
- Oct 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
A Phase 3 trial of roflumilast vehicle cream in atopic dermatitis (AD), sponsored by Arcutis Biotherapeutics. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
roflumilast vehicle cream
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07916480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07916480.